Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment

Kari Esa Jarkko Mikael; Kuusisto Milla Elvi Linnea; Honkavaara PaiviHakalahti AnnaHaapasaari Kirsi-MariaBloigu RistoKarihtala PeeterTeppo Hanna-RiikkaPirinen RistoTurpeenniemi-Hujanen TainaKuittinen Outi

首页> 外文期刊>European Journal of Haematology >Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment

【24h】

Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment

机译：

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Objective In diffuse large B-cell lymphoma (DLBCL), there is an unmet medical need to select patients who would benefit from intensified frontline treatments such as adding etoposide to an R-CHOP regimen.

著录项

来源
《European Journal of Haematology》 |2020年第2期|156-163|共8页
作者
Kari Esa Jarkko Mikael; Kuusisto Milla Elvi Linnea; Honkavaara PaiviHakalahti AnnaHaapasaari Kirsi-MariaBloigu RistoKarihtala PeeterTeppo Hanna-RiikkaPirinen RistoTurpeenniemi-Hujanen TainaKuittinen Outi;
展开▼
作者单位

Univ Oulu, Oulu Univ Hosp, Med Res Ctr, Dept Oncol & Radiotherapy, Oulu, Finland;

Univ Oulu, Dept Pathol, Oulu, Finland;

Univ Oulu, Med Informat & Stat Res Grp, Oulu, FinlandNorth Karelia Cent Hosp, Dept Pathol, Joensuu, FinlandUniv Eastern Finland, Kuopio Univ Hosp, Fac Hlth Med, Inst Clin Med,Dept Oncol, Kuopio, Finland;

展开▼
收录信息
原文格式 PDF
正文语种英语
中图分类血液及淋巴系疾病;
关键词
diffuse large B-cell lymphoma; doxorubicin; etoposide; R-CHOEP; thioredoxin-1;

相似文献

外文文献
中文文献

1. Selecting optimum miRNA panel for miRNA signature-based companion diagnostic model to predict the response of R-CHOP treatment in diffuse large B-cell lymphoma [J] . Nakamura N., Hamada R., Kaneko H.Ohta S. Journal of Bioscience and Bioengineering . 2023,第4期

机译：Selecting optimum miRNA panel for miRNA signature-based companion diagnostic model to predict the response of R-CHOP treatment in diffuse large B-cell lymphoma
2. New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment [J] . Chiche Edmond, Loschi Michael Bulletin du Cancer: Journal de l'Association Francaise pour l'Etude du Cancer . 2022,第9期

机译：New drug approval: Lisocabtagene maraleucel for patients with relapsed or refractory diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma or follicular lymphoma grade 3B after two or more lines of systemic treatment
3. Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma [J] . Zhang Jesse, Disperati Patricia, Elinder-Camburn AnnaMerriman EileenLeitch SophieChan Henry Journal of geriatric oncology . 2022,第4期

机译：Electronic FRAIL score as a predictor of treatment outcomes in older patients with diffuse large B-cell lymphoma
4. PROGNOSTIC SIGNIFICANCE OF MEDIASTINAL MASS IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA CS II – CASE STUDY [O] . Olivera Simonović 2014

机译：pROGNOsTIC sIGNIFICaNCE OF mEDIasTINaL mass IN paTIENTs WITH DIFFUsE LaRGE B-CELL LYmpHOma Cs II – CasE sTUDY

Thioredoxin-1 as a biological predictive marker for selecting diffuse large B-cell lymphoma patients for etoposide-containing treatment

摘要

著录项

相似文献

相关主题

期刊订阅